Scarica l'app Stockscreener
16.11
0.37%
-0.06
Dopo l'orario di chiusura:
15.75
-0.36
-2.23%
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché ADPT Giù?
Forum
Previsione
Precedente Chiudi:
$16.17
Aprire:
$16.17
Volume 24 ore:
3.35M
Relative Volume:
1.49
Capitalizzazione di mercato:
$2.46B
Reddito:
$205.22M
Utile/perdita netta:
$-121.24M
Rapporto P/E:
-19.79
EPS:
-0.8141
Flusso di cassa netto:
$-82.81M
1 W Prestazione:
-1.89%
1M Prestazione:
+9.22%
6M Prestazione:
+36.53%
1 anno Prestazione:
+128.51%
Intervallo 1D:
$15.78
$16.82
Intervallo di 1 settimana:
$15.31
$16.82
Portata 52W:
$5.975
$20.76
Adaptive Biotechnologies Corp Stock (ADPT) Company Profile
Nome
Adaptive Biotechnologies Corp
Settore
Industria
Telefono
206-659-0067
Indirizzo
1165 EASTLAKE AVE E, SEATTLE, WA
Confronta ADPT con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
ADPT
Adaptive Biotechnologies Corp
|
16.11 | 2.47B | 205.22M | -121.24M | -82.81M | -0.8141 |
|
VRTX
Vertex Pharmaceuticals Inc
|
468.38 | 113.87B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
776.54 | 80.22B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
406.40 | 52.56B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
803.74 | 49.31B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
175.07 | 37.37B | 447.02M | -1.18B | -906.14M | -6.1812 |
Adaptive Biotechnologies Corp Stock (ADPT) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-12-02 | Ripresa | Morgan Stanley | Equal-Weight |
| 2025-09-30 | Iniziato | Guggenheim | Buy |
| 2025-06-18 | Iniziato | Craig Hallum | Buy |
| 2025-03-21 | Aggiornamento | Goldman | Neutral → Buy |
| 2023-07-05 | Ripresa | JP Morgan | Overweight |
| 2023-01-05 | Iniziato | Scotiabank | Sector Outperform |
| 2022-12-21 | Aggiornamento | Piper Sandler | Neutral → Overweight |
| 2022-08-25 | Iniziato | Credit Suisse | Underperform |
| 2022-06-03 | Iniziato | Piper Sandler | Neutral |
| 2022-02-16 | Reiterato | BTIG Research | Buy |
| 2022-02-16 | Reiterato | BofA Securities | Buy |
| 2022-02-16 | Reiterato | Goldman | Neutral |
| 2022-02-16 | Reiterato | JP Morgan | Overweight |
| 2021-10-15 | Ripresa | Cowen | Outperform |
| 2021-03-03 | Downgrade | Goldman | Buy → Neutral |
| 2020-10-08 | Ripresa | BTIG Research | Buy |
| 2020-09-09 | Iniziato | Morgan Stanley | Equal-Weight |
| 2020-06-03 | Iniziato | Goldman | Buy |
| 2019-07-23 | Iniziato | BTIG Research | Buy |
| 2019-07-22 | Iniziato | BofA/Merrill | Buy |
| 2019-07-22 | Iniziato | Cowen | Outperform |
| 2019-07-22 | Iniziato | Goldman | Neutral |
| 2019-07-22 | Iniziato | Guggenheim | Buy |
| 2019-07-22 | Iniziato | William Blair | Outperform |
Mostra tutto
Adaptive Biotechnologies Corp Borsa (ADPT) Ultime notizie
Adaptive Biotechnologies discloses it's raising $15 million for subsidiary - The Business Journals
Adaptive Biotechnologies to Present at the 44th Annual J.P. Morgan Healthcare Conference - The Manila Times
Biotech company heads to major healthcare conference in San Francisco - Stock Titan
Adaptive Biotechnologies announces subsidiary’s Series A financing round By Investing.com - Investing.com Nigeria
Adaptive Biotechnologies CorpUnit held initial closing $15 million Series A financingSEC filing - marketscreener.com
Adaptive Biotechnologies announces subsidiary’s Series A financing round - Investing.com
Adaptive Biotechnologies Announces Series A Financing for Subsidiary - TradingView — Track All Markets
Adaptive biotechnologies CPO Lo sells $76,895 in ADPT stock - Investing.com
Adaptive biotechnologies CPO Lo sells $76,895 in ADPT stock By Investing.com - Investing.com UK
Adaptive Biotechnologies: 2026 Is The Durability Test, Not The Hype Cycle (ADPT) - Seeking Alpha
Adaptive Biotechnologies (ADPT) Leads Life Sciences Sector with 183.57% YTD Gain - GuruFocus
Adaptive Biotechnologies (ADPT): Valuation Check After New Pfizer T-Cell Discovery and AI Drug Collaboration Deals - simplywall.st
Adaptive Biotechnologies is the top performing life sciences tools and services stock YTD (ADPT:NASDAQ) - Seeking Alpha
Adaptive Biotechnologies (ADPT) Is Up 10.1% After New Pfizer TCR-AI Collaboration Milestone DealWhat's Changed - simplywall.st
Will Adaptive Biotechnologies Corporation stock see PE expansionTrade Risk Summary & Real-Time Market Trend Scan - Улправда
How Adaptive Biotechnologies Corporation (1HM) stock trades after rate cutsGlobal Markets & High Accuracy Trade Signal Alerts - Улправда
How Adaptive Biotechnologies Corporation stock responds to policy changesMarket Activity Recap & Fast Moving Stock Trade Plans - Улправда
First Week of February 2026 Options Trading For Adaptive Biotechnologies (ADPT) - Nasdaq
Why Adaptive Biotechnologies Corporation stock remains undervaluedJuly 2025 Technicals & Trade Opportunity Analysis Reports - Улправда
Adaptive Biotechnologies Insider Sold Shares Worth $1,773,267, According to a Recent SEC Filing - marketscreener.com
Adaptive Biotechnologies Exec Sells Shares Under Trading Plan - TradingView — Track All Markets
Officer Lo Sells 113,890 ($1.8M) Of Adaptive Biotechnologies Corp [ADPT] - TradingView — Track All Markets
Adaptive Biotechnologies (ADPT): Valuation Check After New Pfizer Collaborations and Surging 2024 Share Price - simplywall.st
Adaptive Biotechnologies stock rises after Pfizer deals worth up to $890M - Investing.com
Pfizer Faces Another Quiet Year As Patent Losses Cloud 2026 Outlook: Analyst - Benzinga
Adaptive Biotechnologies inks two agreements with Pfizer in immunology - Investing.com India
Adaptive signs deal with Pfizer worth up to $890 million for rheumatoid arthritis research - Reuters
Adaptive Biotechnologies stock rises after Pfizer deals worth up to $890M By Investing.com - Investing.com South Africa
Adaptive Biotechnologies signs non-exclusive deals with Pfizer worth up to $890 million - Yahoo Finance
Adaptive Biotechnologies Announces Two Immune Receptor Licensing Agreements with Pfizer - The Manila Times
How Investors Are Reacting To Adaptive Biotechnologies (ADPT) clonoSEQ Data Shaping MRD-Guided Cancer Care - Yahoo Finance
Insider Sell: Robert Hershberg Sells 22,968 Shares of Adaptive B - GuruFocus
Adaptive Biotechnologies Director Sells Shares - TradingView — Track All Markets
Adaptive Biotechnologies (ADPT) falls 24.5% as execs dispose millions of stake - MSN
Dir Hershberg Files To Sell 22,968 Of Adaptive Biotechnologies Corp [ADPT] - TradingView — Track All Markets
Take off with Adaptive Biotechnologies Corp (ADPT): Get ready for trading - setenews.com
Adaptive Biotechnologies to Participate in Jefferies Fireside Chat Series on Minimal Residual Disease - The Manila Times
Adaptive Biotechnologies to Discuss clonoSEQ Technology and Minimal Residual Disease at Jefferies Fireside Chat - Quiver Quantitative
Adaptive Biotechnologies (Nasdaq: ADPT) to discuss MRD, clonoSEQ at Jefferies chat - Stock Titan
Adaptive Biotechnologies chief commercial officer sells $212k in stock - Investing.com
Adaptive Biotechnologies (ADPT) Falls 24.5% as Execs Dispose Millions of Stake - Insider Monkey
Adaptive Biotechnologies CEO Chad M Robins Sells $3M in Company Shares - StocksToTrade
Adaptive Biotechnologies (ADPT) Showcases clonoSEQ Test Advances at ASH Meeting - GuruFocus
Adaptive Biotechnologies Stock Declines After Insider Sale - timothysykes.com
December Disappointments: 10 Big Names Troubled Early - Insider Monkey
Seattle InnoLayoffs at Adaptive I Rover's marketing efforts - The Business Journals
Adaptive Biotechnologies’ Stock Faces Turmoil Amid Insider Selling - StocksToTrade
Adaptive Biotechnologies Corporation Showcases Leadership in Hematology-Oncology MRD with New clonoSEQ Data Driving Treatment Interventions at 2025 ASH Annual Meeting - marketscreener.com
Adaptive Biotechnologies Highlights Expanded Clinical Use of clonoSEQ® Test at 67th ASH Annual Meeting - Quiver Quantitative
Adaptive Biotechnologies Showcases Leadership in Hematology-Oncology MRD with New clonoSEQ® Data Driving Treatment Interventions at 2025 ASH Annual Meeting - The Manila Times
Adaptive Biotechnologies (Nasdaq: ADPT) shows clonoSEQ MRD guiding blood cancer care at ASH 2025 - Stock Titan
Adaptive Biotechnologies Corp Azioni (ADPT) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
2.52%
0.07%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):